Remuneration Information • Jun 19, 2020
Remuneration Information
Open in ViewerOpens in native device viewer
National Storage Mechanism | Additional information
RNS Number : 4363Q
Synairgen plc
19 June 2020
Press Release
Synairgen plc
('Synairgen' or the 'Company')
Grant of options
Southampton, UK - 19 June 2020: Synairgen plc (LSE: SNG), the respiratory drug discovery and development company, announces that on 18 June 2020 the Board of Synairgen granted options ('Options') over 1,767,985 ordinary shares of one pence each in the capital of the Company ('Ordinary Shares') at an exercise price of one pence per Ordinary Share. The Options represent in aggregate 1.18 per cent. of the Company's issued share capital.
The Options are issued under the Company's existing Long Term Incentive Plan and are exercisable between 18 June 2023 and 17 June 2030, subject to achievement of performance criteria related to the increase in the total shareholder return of the Company. Following this grant, Synairgen has 10,255,500 options in issue, representing 6.86 per cent. of the Company's issued share capital.
Included in the number of Options granted on 18 June 2020, the following Options were issued to directors:
| Director | Options Issued |
| Richard Marsden | 490,817 |
| Dr. Phillip Monk | 354,483 |
| John Ward | 381,749 |
Following the issue of the Options, the interests of the directors of the Company at
18 June 2020 are as follows:
| Director | Total options | Ordinary shares | Total interest | Percentage holding of fully diluted share capital |
| Richard Marsden | 3,533,839 | 367,825 | 3,901,664 | 2.44% |
| Dr. Phillip Monk | 1,948,582 | 244,600 | 2,193,182 | 1.37% |
| John Ward | 2,481,064 | 367,577 | 2,848,641 | 1.78% |
| Simon Shaw | - | 1,531,239 | 1,531,239 | 0.96% |
| Iain Buchanan | 212,765 | 112,741 | 325,506 | 0.20% |
| Dr. Bruce Campbell | - | 322,830 | 322,830 | 0.20% |
| Prof. Stephen Holgate | - | 886,931 | 886,931 | 0.56% |
Jody Brookes and Victoria Tear, also persons disclosing managerial responsibilities, were granted 135,576 and 101,270 Options respectively.
This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No. 596/2014 ('MAR')
For further information, please contact:
Synairgen plc
Richard Marsden, Chief Executive Officer
John Ward, Finance Director
Tel: + 44 (0) 23 8051 2800
finnCap
Geoff Nash, Kate Bannatyne, Charlie Beeson (Corporate Finance)
Alice Lane, Manasa Patil (ECM)
Tel: + 44 (0) 20 7220 0500
Consilium Strategic Communications (Financial Media and Investor
Relations)
Mary-Jane Elliott, Sue Stuart, Olivia Manser
Tel: +44 (0) 20 3709 5700
Notes for Editors
About Synairgen
Synairgen is a respiratory drug discovery and development company founded by University of Southampton Professors Stephen Holgate, Donna Davies and Ratko Djukanovic. The business, focused primarily on lung viral defence in asthma and COPD, uses its differentiating human biology BioBank platform and world-renowned international academic KOL network to discover and develop novel therapies for respiratory disease.
Synairgen is quoted on AIM (LSE: SNG). For more information about Synairgen, please see www.synairgen.com
| 1. | Details of Persons Discharging Managerial Responsibilities ('PDMR') / person closely associated with them ('PCA') | |
| a) | Name | Richard Marsden |
| 2. | Reason for notification | |
| a) | Position / status | Chief Executive Officer |
| b) | Initial notification / amendment | Initial Notification |
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
| a) | Name | Synairgen plc |
| b) | LEI | 213800IMMTOPPDF8HD24 |
| 4. | Details of the transaction(s): | |
| a) | Description of the financial instrument Identification code |
Options over ordinary shares of 1p each GB00B0381Z20 |
| b) | Nature of the transaction | Award of Options under the Synairgen LTIP |
| c) | Price(s) and volume(s) | 490,817 Options awarded |
| d) | Aggregated information Aggregated volume Price |
n/a |
| e) | Date of the transaction | 18 June 2020 |
| f) | Place of the transaction | Outside a trading venue |
| 1. | Details of Persons Discharging Managerial Responsibilities ('PDMR') / person closely associated with them ('PCA') | |
| a) | Name | Dr Phillip Monk |
| 2. | Reason for notification | |
| a) | Position / status | Chief Scientific Officer |
| b) | Initial notification / amendment | Initial Notification |
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
| a) | Name | Synairgen plc |
| b) | LEI | 213800IMMTOPPDF8HD24 |
| 4. | Details of the transaction(s): | |
| a) | Description of the financial instrument Identification code |
Options over ordinary shares of 1p each GB00B0381Z20 |
| b) | Nature of the transaction | Award of Options under the Synairgen LTIP |
| c) | Price(s) and volume(s) | 354,483 Options awarded |
| d) | Aggregated information Aggregated volume Price |
n/a |
| e) | Date of the transaction | 18 June 2020 |
| f) | Place of the transaction | Outside a trading venue |
| 1. | Details of Persons Discharging Managerial Responsibilities ('PDMR') / person closely associated with them ('PCA') | |
| a) | Name | John Ward |
| 2. | Reason for notification | |
| a) | Position / status | Finance Director |
| b) | Initial notification / amendment | Initial Notification |
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
| a) | Name | Synairgen plc |
| b) | LEI | 213800IMMTOPPDF8HD24 |
| 4. | Details of the transaction(s): | |
| a) | Description of the financial instrument Identification code |
Options over ordinary shares of 1p each GB00B0381Z20 |
| b) | Nature of the transaction | Award of Options under the Synairgen LTIP |
| c) | Price(s) and volume(s) | 381,749 Options awarded |
| d) | Aggregated information Aggregated volume Price |
n/a |
| e) | Date of the transaction | 18 June 2020 |
| f) | Place of the transaction | Outside a trading venue |
| 1. | Details of Persons Discharging Managerial Responsibilities ('PDMR') / person closely associated with them ('PCA') | |
| a) | Name | Jody Brookes |
| 2. | Reason for notification | |
| a) | Position / status | Head of Clinical Operations |
| b) | Initial notification / amendment | Initial Notification |
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
| a) | Name | Synairgen plc |
| b) | LEI | 213800IMMTOPPDF8HD24 |
| 4. | Details of the transaction(s): | |
| a) | Description of the financial instrument Identification code |
Options over ordinary shares of 1p each GB00B0381Z20 |
| b) | Nature of the transaction | Award of Options under the Synairgen LTIP |
| c) | Price(s) and volume(s) | 135,576 Options awarded |
| d) | Aggregated information Aggregated volume Price |
n/a |
| e) | Date of the transaction | 18 June 2020 |
| f) | Place of the transaction | Outside a trading venue |
| 1. | Details of Persons Discharging Managerial Responsibilities ('PDMR') / person closely associated with them ('PCA') | |
| a) | Name | Victoria Tear |
| 2. | Reason for notification | |
| a) | Position / status | Head of Laboratories |
| b) | Initial notification / amendment | Initial Notification |
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
| a) | Name | Synairgen plc |
| b) | LEI | 213800IMMTOPPDF8HD24 |
| 4. | Details of the transaction(s): | |
| a) | Description of the financial instrument Identification code |
Options over ordinary shares of 1p each GB00B0381Z20 |
| b) | Nature of the transaction | Award of Options under the Synairgen LTIP |
| c) | Price(s) and volume(s) | 101,270 Options awarded |
| d) | Aggregated information Aggregated volume Price |
n/a |
| e) | Date of the transaction | 18 June 2020 |
| f) | Place of the transaction | Outside a trading venue |
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
END
MSCEAPKPFSXEEFA
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.